Results 131 to 140 of about 47,533 (300)

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Globo‐H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer

International Journal of Cancer, EarlyView.
What's New? Colorectal cancer (CRC) is increasingly complicated by drug‐resistant tumors that limit the effectiveness of anticancer therapies. Because resistance mechanisms vary among patients and can evolve over time, personalized treatment strategies are needed.
Keren Zohar, Marco Strecker, Thomas Wartmann, Wenjie Shi, Frederike Stelter, Maximilian Doelling, Mihailo Andric, Or Kakhlon, Christian Täger, Denny Schanze, Michael Linnebacher, Michael Naumann, Daniel E. Stange, Dörthe Jechorek, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Complexation between oleanolic and maslinic acids with native and modified cyclodextrins [PDF]

, 2018
Oleanolic (OA) and maslinic (MA) acids are two natural triterpenoids with a wide range of beneficial effects for human health. However, their low solubility and permeability make their application in the food or industry difficult. The complexation of OA
López Miranda, Santiago
core   +2 more sources

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, EarlyView.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. [PDF]

, 2014
Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred
Janku, Filip, Kaseb, Ahmed O, Kurzrock, Razelle, Tsimberidou, Apostolia M, Wolff, Robert A   +4 more
core   +3 more sources

Tiny carriers, big impact: How Fusobacterium nucleatum extracellular vesicles drive oral diseases and beyond

Interdisciplinary Medicine, EarlyView.
This review explores how Fusobacterium nucleatum extracellular vesicles drive local oral diseases and distal pathologies via sophisticated cross‐compartment cross talk. It highlights the transformative potential of these “tiny carriers” as next‐generation molecular intermediaries for advanced health monitoring and innovative bio‐interventions by ...
Rongyang Ma, Jiahui Huang, Yitong Chen, Haoxuan Wang, Hang Zou, Wanghong Zhao, Zilong Deng   +6 more
wiley   +1 more source

New Hydrazone Derivatives Featuring Isatin and Piperazine Moieties: Synthesis, Cytotoxicity Evaluation, and Molecular Modeling Studies

Journal of Applied Toxicology, EarlyView.
ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü, Münevver Baran, Miyase Gözde Gündüz, Şengül Dilem Doğan   +3 more
wiley   +1 more source

Emerging treatment options for BRAF-mutant colorectal cancer. [PDF]

, 2018
The personalization of cancer care is rooted in the premise that there are subsets of patients with tumors harboring clinically relevant targets for patient-specific treatments.
Atreya, Chloe E, Ursem, Carling, Van Loon, Katherine   +2 more
core   +2 more sources

Machine Learning‐Driven Predictive Modeling and Multi‐Objective Exploration of Oxaliplatin‐Loaded Nanocarriers for Enhanced Loading and Encapsulation Efficiency

Materials Genome Engineering Advances, EarlyView.
Integrating ML and multi‐objective optimization enabled efficient, accurate design of nanocarriers with optimized loading and encapsulation efficiencies. ABSTRACT Oxaliplatin (OXA), a critical third‐generation platinum chemotherapeutic, is significantly limited by suboptimal loading capacity and encapsulation efficiency in nanoparticle‐based delivery ...
Abbas Rahdar, Maryam Shirzad, Sonia Fathi‐Karkan, M. Ali Aboudzadeh   +3 more
wiley   +1 more source

EPMA position paper in cancer:current overview and future perspectives [PDF]

, 2015
At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive, and personalized medicine (PPPM). Individual patients will participate in more aspects of their healthcare.
Bubnov, Rostylav, Danesi, Romano, Desiderio, Dominic M., Grech, Godfrey, Hagan, Suzanne, Vittadini, Giorgio, Yoo, Byong Chul, Zhan, Xianquan   +7 more
core   +5 more sources